Correlation Between Immunome and Annovis Bio
Can any of the company-specific risk be diversified away by investing in both Immunome and Annovis Bio at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Immunome and Annovis Bio into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Immunome and Annovis Bio, you can compare the effects of market volatilities on Immunome and Annovis Bio and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Immunome with a short position of Annovis Bio. Check out your portfolio center. Please also check ongoing floating volatility patterns of Immunome and Annovis Bio.
Diversification Opportunities for Immunome and Annovis Bio
0.11 | Correlation Coefficient |
Average diversification
The 3 months correlation between Immunome and Annovis is 0.11. Overlapping area represents the amount of risk that can be diversified away by holding Immunome and Annovis Bio in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Annovis Bio and Immunome is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Immunome are associated (or correlated) with Annovis Bio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Annovis Bio has no effect on the direction of Immunome i.e., Immunome and Annovis Bio go up and down completely randomly.
Pair Corralation between Immunome and Annovis Bio
Given the investment horizon of 90 days Immunome is expected to generate 0.69 times more return on investment than Annovis Bio. However, Immunome is 1.45 times less risky than Annovis Bio. It trades about 0.08 of its potential returns per unit of risk. Annovis Bio is currently generating about 0.02 per unit of risk. If you would invest 314.00 in Immunome on September 12, 2024 and sell it today you would earn a total of 1,013 from holding Immunome or generate 322.61% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Immunome vs. Annovis Bio
Performance |
| Timeline |
| Immunome |
| Annovis Bio |
Immunome and Annovis Bio Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Immunome and Annovis Bio
The main advantage of trading using opposite Immunome and Annovis Bio positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Immunome position performs unexpectedly, Annovis Bio can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Annovis Bio will offset losses from the drop in Annovis Bio's long position.| Immunome vs. Anebulo Pharmaceuticals | Immunome vs. Adagene | Immunome vs. Acrivon Therapeutics, Common | Immunome vs. AnaptysBio |
| Annovis Bio vs. Cassava Sciences | Annovis Bio vs. Axsome Therapeutics | Annovis Bio vs. Reviva Pharmaceuticals Holdings | Annovis Bio vs. Seres Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Complementary Tools
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |